Clinical Trials Browser

Unknown × pembrolizumab × Breast × Clear all

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT03789097 2024-01-30

Vaccination With Flt3L, Radiation, and Poly-ICLC

Phase 1/2 Unknown

56 enrolled

BreastHead & NeckLymphoid

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Lymphoma, Lymphoma, Non-Hodgkin

NCT05708950 2023-07-13

A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)

Phase 1/2 Unknown

314 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Breast Neoplasms, Carcinoma, Colonic Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms

NCT03567720 2023-06-01

Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC

Phase 2 Unknown

65 enrolled

Breast

Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT05681728 2023-01-12

A Phase II Study Evaluating the Efficacy and Safety of Pembrolizumab in Combination With Chemotherapy as Neoadjuvant Therapy for Triple-negative Breast Cancer

Phase 2 Unknown

26 enrolled

Breast

Breast Neoplasms

NCT03492918 2022-03-15

Pembrolizumab in Combination With Paclitaxel in the Hormone Receptor-positive Metastatic Breast Cancer With High Tumor Mutational Burden Selected by Whole Exome Sequencing: Korean Cancer Study Group Trial (KCSG BR20-16)

Phase 2 Unknown

30 enrolled

Breast

Breast Neoplasms

NCT03145961 2022-02-24

c-TRAK-TN

Phase 2 Unknown

208 enrolled

Breast

Triple Negative Breast Neoplasms

NCT04946227 2021-06-30

Pembrolizumab and Paclitaxel in Hormone Receptor-positive, hyperMUTATted Metastatic Breast Cancer Identified by Whole exOme sequeNcing ('MUTATION2')

Phase 2 Unknown

52 enrolled

Breast

Breast Neoplasms

NCT04024800 2021-06-02

NSABP FB-14

Phase 2 Unknown

29 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04683445 2020-12-24

Efficacy and Safety of Eribulin in the Treatment of Advanced Breast Cancer

Unknown

80 enrolled

Breast

Breast Neoplasms

NCT03044730 2020-07-13

Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery

Phase 2 Unknown

30 enrolled 11 charts

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03544723 2020-06-09

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

Phase 2 Unknown

40 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicLymphoidThoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Hodgkin Disease, Liver Neoplasms, Lymphoma, Melanoma, Stomach Neoplasms, Carcinoma, Merkel Cell, Neoplasms, Squamous Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT03879174 2019-03-18

Pembro

Phase 2 Unknown

25 enrolled

Breast

Breast Cancer Female

Clinical Trials

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

Vaccination With Flt3L, Radiation, and Poly-ICLC

A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)

Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC

A Phase II Study Evaluating the Efficacy and Safety of Pembrolizumab in Combination With Chemotherapy as Neoadjuvant Therapy for Triple-negative Breast Cancer

Pembrolizumab in Combination With Paclitaxel in the Hormone Receptor-positive Metastatic Breast Cancer With High Tumor Mutational Burden Selected by Whole Exome Sequencing: Korean Cancer Study Group Trial (KCSG BR20-16)

c-TRAK-TN

Pembrolizumab and Paclitaxel in Hormone Receptor-positive, hyperMUTATted Metastatic Breast Cancer Identified by Whole exOme sequeNcing ('MUTATION2')

NSABP FB-14

Efficacy and Safety of Eribulin in the Treatment of Advanced Breast Cancer

Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

Pembro